NASDAQ:AMRX | Free Cash Flow | Amneal Pharmaceuticals, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2016-12-31 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$26.74M$8.18M-$34.92M-56.09%
2025-12-31$130.32M$21.77M$108.54M309.45%
2025-03-31$7.41M$13.16M-$5.75M-47.18%
2024-12-31$118.08M$15.16M$102.92M
2024-03-31-$4.41M$9.2M-$13.61M
2023-12-31$135.82M$9.87M$125.96M
2023-03-31$139.71M$9.69M$130.02M
2022-12-31-$23.29M$11.47M-$34.76M
2022-03-31$120.34M$10.79M$109.55M
2021-12-31$63.26M$17.5M$45.76M
2021-03-31$148.13M$11.78M$136.35M1069.51%
2020-12-31$105.96M$29.53M$76.43M
2020-03-31$49.03M$7.37M$41.66M34.59%
2019-12-31-$50.89M$4.52M-$55.41M
2019-03-31-$108.41M$17.99M-$126.4M
2018-12-31$259.65M$20.02M$239.63M
2018-03-31$27.03M$19.5M$7.53M
2017-12-31$65.27M$24.62M$40.65M

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31$339.99M$70.06M$269.93M374.60%
2024-12-31$295.1M$51.92M$243.18M
2023-12-31$345.58M$43.22M$302.36M
2022-12-31$65.1M$46.41M$18.69M
2021-12-31$241.82M$47.73M$194.09M1474.53%
2020-12-31$379M$56.45M$322.56M475.81%
2019-12-31$1.71M$47.18M-$45.48M
2018-12-31$250.23M$83.09M$167.14M
2017-12-31$234.19M$94.77M$139.42M
2016-12-31$115.06M$122.76M-$7.7M